Clinical Trial Update: AMG 335 Expanded Access Program for IgG4-Related Disease

View source ↗

Summary

Amgen's update notes that AMG 335 (talquetamab) Expanded Access is available for patients with IgG4-related disease, under the Amgen program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• AMG-335 (talquetamab)

Snippet

Sponsor: Amgen | Status: AVAILABLE